This is an aggregated industry headline. Read the full story at AJMC →
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfo…
The WeekFierceBiotech ↗
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a de…
The WeekBriefing
CMS’s proposed 2027 OPPS rule would cut 340B drug reimbursement from ASP plus 6% to ASP minus 33.4%. The savin…